Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Clever Leaves Holdings Inc. (CLVR) vs Organigram Global Inc. (OGI)

Clever Leaves Holdings Inc. and Organigram Global Inc. are both Drug Manufacturers Specialty & Generic companies. Organigram Global Inc. is the larger, with a market value of $155.1M against $96.5M — 1.6× the size. Clever Leaves Holdings Inc. has negative trailing earnings, so its P/E is not meaningful; Organigram Global Inc. trades at 2.4×. Organigram Global Inc. grew revenue faster over the last twelve months: 39.5% against 6.14%. Organigram Global Inc. has the higher net margin (28.4% vs −102.8%) and the higher return on invested capital (−1.53% vs −52.6%). Across the 16 metrics below, Organigram Global Inc. leads on 11 and Clever Leaves Holdings Inc. on 5.

Valuation

Metric CLVR OGI Drug Manufacturers Specialty & Generic median
P/E n/m 2.37 20.14
P/S n/m 0.67 2.25
P/B n/m 0.42 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 0.45 16.79 12.29
EV/Sales (0.33) 0.70 2.56
Earnings yield 0.00% 42.26% (2.99%)
Free cash flow yield 0.00% (14.22%) 0.00%

Profitability

Metric CLVR OGI Drug Manufacturers Specialty & Generic median
Gross margin 37.64% 36.47% 53.94%
Operating margin (89.53%) (3.91%) 0.00%
Net margin (102.77%) 28.44% 0.00%
Free cash flow margin (49.82%) (9.46%) 0.00%
Return on equity (55.39%) 20.20% (0.40%)
Return on assets (42.95%) 12.70% (3.32%)
Return on invested capital (52.59%) (1.53%) 0.00%

Growth

Metric CLVR OGI Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 6.14% 39.51% 10.01%
EPS growth (last fiscal year) 77.89% 60.00% —
Revenue growth, 5-year CAGR — 24.30% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLVR OGI Drug Manufacturers Specialty & Generic median
Debt to equity 0.05 0.04 0.05
Current ratio 2.40 2.61 2.31
Net debt to EBITDA 0.45 (31.56) 0.85

Dividend

Metric CLVR OGI Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric CLVR OGI Drug Manufacturers Specialty & Generic median
Market cap 96.49m 155.11m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack